Zyvana 2 Tablet contains Glimepiride 2 mg, an oral hypoglycemic agent belonging to the sulfonylurea class, primarily indicated for the management of type 2 diabetes mellitus. Glimepiride functions by stimulating pancreatic beta cells to release insulin, thereby improving glycemic control in patients with insufficient endogenous insulin production. It is typically prescribed as an adjunct to diet and exercise to achieve optimal blood glucose levels. Zyvana 2 is effective in reducing both fasting and postprandial blood glucose concentrations, contributing to the prevention of long-term diabetic complications such as neuropathy, retinopathy, and nephropathy. The tablet should be administered once daily with breakfast or the first main meal to minimize the risk of hypoglycemia. Dosage adjustments may be required based on patient response and glycemic targets. Caution is advised in patients with hepatic or renal impairment, and it is contraindicated in individuals with type 1 diabetes, diabetic ketoacidosis, or known hypersensitivity to sulfonylureas. Common adverse effects include hypoglycemia, weight gain, and gastrointestinal disturbances. Regular monitoring of blood glucose and HbA1c levels is recommended to assess therapeutic efficacy and safety. Zyvana 2 should be used under medical supervision as part of a comprehensive diabetes management plan.